Join us for a global CMT research convention,
an event to bring together the CMT research community and the CMT patient community
in a single event.

If you have any issues please contact Vanessa Sanchez at [email protected] or +1 (404) 474-8805

The CMT Research Foundation is laser-focused on delivering treatments and cures for Charcot-Marie-Tooth disease during our lifetime.

The 2021 Global CMT Research Convention will unite researchers, pharma companies, government and patients to discuss and try to find solutions for the most pressing problems in CMT research.

Come learn what the future holds for CMT and how you can help end this disease!

For the Research Community

September 24th

A day for researchers, industry and government agencies to:

SHARE the latest in CMT drug development research

UNITE their voices and streamline their work

EXAMINE the most pressing issues facing CMT drug development


Click here to see the full day of event agenda

Jim Wilson, MD, PhD

University of Pennsylvania

Keynote Speaker

Robert "Bob" Baloh, MD, PhD



Zarife Sahenk, MD, PhD

Nationwide Children’s Hospital

United States

Kleopas Kleopa, MD

Cyprus Institute of Neurology & Genetics


For the Patient Community

September 25th

A day for the patient community to:

LEARN about recent developments and clinical trials in CMT

INTERACT with key research experts

ACT to advance treatments for CMT


Click here to see the full day of event agenda

Artie Suckow, PhD

DTx Pharma

Keynote Speaker

Amanda Haidet-Phillips, PhD

Novartis Gene Therapies

United States

David Herrmann, MBBCh

University of Rochester

United States

William Motley, MD, DPhil

Flare Therapeutics

United States

Thank You to Our Sponsors!

The Scientific Programming Committee

Marina Kennerson, PhD – Chair
Professor of Neurogenetics and Neuroscience ANZAC Research Institute and University of Sydney, Australia
Carla Taveggia, PhD – Vice Chair

Director, Division of Neuroscience Ospedale San Raffaele, Milan, Italy

Charles Abrams, MD, PhD

Professor of Neurology and Rehabilitation
University of Illinois, Chicago (UIC)

Paul August, PhD

Vice President of Biology
Agios Pharmaceuticals

Robert Burgess, PhD

Professor, The Rare and Orphan Disease Center
The Jackson Laboratory

Amanda Haidet-Phillips, PhD

Senior Director, Translational Medicine
Novartis Gene Therapies

Glen Nuckolls, PhD

Program Director, Neurogenetics, Division of Neuroscience
U.S. National Institute of Neurological Disorders and Stroke (NINDS)

Jonathan Sabbagh, PhD

Scientific Portfolio Director
Muscular Dystrophy Association

Tiina Urv, PhD

Program Director, Office of Rare Diseases Research
U.S. National Center for Advancing Translational Sciences (NCATS)